Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GLYC's Cash to Debt is ranked higher than
75% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. GLYC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GLYC' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6648
N/A
No Debt
Equity to Asset 0.84
GLYC's Equity to Asset is ranked higher than
69% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. GLYC: 0.84 )
Ranked among companies with meaningful Equity to Asset only.
GLYC' s Equity to Asset Range Over the Past 10 Years
Min: 0.55  Med: 0.84 Max: 0.95
Current: 0.84
0.55
0.95
F-Score: 3
Z-Score: 11.60
M-Score: 36.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -66.00
GLYC's Operating margin (%) is ranked higher than
51% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. GLYC: -66.00 )
Ranked among companies with meaningful Operating margin (%) only.
GLYC' s Operating margin (%) Range Over the Past 10 Years
Min: -265.19  Med: -74.13 Max: 24
Current: -66
-265.19
24
Net-margin (%) -65.85
GLYC's Net-margin (%) is ranked higher than
52% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. GLYC: -65.85 )
Ranked among companies with meaningful Net-margin (%) only.
GLYC' s Net-margin (%) Range Over the Past 10 Years
Min: -265.61  Med: -74.01 Max: 23.96
Current: -65.85
-265.61
23.96
ROE (%) -29.56
GLYC's ROE (%) is ranked higher than
51% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. GLYC: -29.56 )
Ranked among companies with meaningful ROE (%) only.
GLYC' s ROE (%) Range Over the Past 10 Years
Min: -137.43  Med: -41.42 Max: 34.84
Current: -29.56
-137.43
34.84
ROA (%) -25.87
GLYC's ROA (%) is ranked higher than
51% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. GLYC: -25.87 )
Ranked among companies with meaningful ROA (%) only.
GLYC' s ROA (%) Range Over the Past 10 Years
Min: -89.49  Med: -24.15 Max: 15.45
Current: -25.87
-89.49
15.45
ROC (Joel Greenblatt) (%) -405.95
GLYC's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. GLYC: -405.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLYC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2627.95  Med: -1944.15 Max: 1067.64
Current: -405.95
-2627.95
1067.64
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

GLYC Guru Trades in Q2 2015

Jim Simons 59,300 sh (+40.19%)
» More
Q3 2015

GLYC Guru Trades in Q3 2015

Jim Simons 47,800 sh (-19.39%)
» More
Q4 2015

GLYC Guru Trades in Q4 2015

Jim Simons 60,921 sh (+27.45%)
» More
Q1 2016

GLYC Guru Trades in Q1 2016

Jim Simons 69,200 sh (+13.59%)
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:PETX, NAS:CMRX, XKRX:041910, ROCO:1760, XKRX:011000, NAS:CRIS » details
Traded in other countries:GKO.Germany,
GlycoMimetics Inc is a clinical stage biotechnology company. The Company is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Ratios

vs
industry
vs
history
Forward P/E 6.98
GLYC's Forward P/E is ranked higher than
90% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. GLYC: 6.98 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.66
GLYC's P/B is ranked lower than
60% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. GLYC: 4.66 )
Ranked among companies with meaningful P/B only.
GLYC' s P/B Range Over the Past 10 Years
Min: 1.81  Med: 2.71 Max: 5.3
Current: 4.66
1.81
5.3
P/S 8.53
GLYC's P/S is ranked higher than
65% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. GLYC: 8.53 )
Ranked among companies with meaningful P/S only.
GLYC' s P/S Range Over the Past 10 Years
Min: 3.94  Med: 9.50 Max: 927.65
Current: 8.53
3.94
927.65
EV-to-EBIT -9.45
GLYC's EV-to-EBIT is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. GLYC: -9.45 )
Ranked among companies with meaningful EV-to-EBIT only.
GLYC' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.1  Med: -8.60 Max: -2.2
Current: -9.45
-26.1
-2.2
EV-to-EBITDA -9.59
GLYC's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. GLYC: -9.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLYC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.9  Med: -8.70 Max: -2.2
Current: -9.59
-26.9
-2.2
Current Ratio 6.95
GLYC's Current Ratio is ranked higher than
65% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. GLYC: 6.95 )
Ranked among companies with meaningful Current Ratio only.
GLYC' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 7.95 Max: 21.83
Current: 6.95
2.14
21.83
Quick Ratio 6.95
GLYC's Quick Ratio is ranked higher than
66% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. GLYC: 6.95 )
Ranked among companies with meaningful Quick Ratio only.
GLYC' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 7.95 Max: 21.83
Current: 6.95
2.14
21.83
Days Sales Outstanding 1.07
GLYC's Days Sales Outstanding is ranked higher than
97% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. GLYC: 1.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLYC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.53  Med: 0.62 Max: 0.71
Current: 1.07
0.53
0.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.95
GLYC's Price/Net Cash is ranked higher than
61% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. GLYC: 4.95 )
Ranked among companies with meaningful Price/Net Cash only.
GLYC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.29  Med: 2.80 Max: 5.59
Current: 4.95
2.29
5.59
Price/Net Current Asset Value 4.87
GLYC's Price/Net Current Asset Value is ranked higher than
61% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. GLYC: 4.87 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GLYC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.25  Med: 2.78 Max: 5.54
Current: 4.87
2.25
5.54
Price/Tangible Book 4.71
GLYC's Price/Tangible Book is ranked higher than
52% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. GLYC: 4.71 )
Ranked among companies with meaningful Price/Tangible Book only.
GLYC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.19  Med: 2.69 Max: 5.49
Current: 4.71
2.19
5.49
Price/Median PS Value 0.90
GLYC's Price/Median PS Value is ranked higher than
67% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. GLYC: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
GLYC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.6  Med: 0.97 Max: 102.06
Current: 0.9
0.6
102.06
Earnings Yield (Greenblatt) (%) -10.59
GLYC's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. GLYC: -10.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLYC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -57.31  Med: 0.00 Max: 0
Current: -10.59
-57.31
0

More Statistics

Revenue (TTM) (Mil) $20.07
EPS (TTM) $ -0.74
Short Percentage of Float2.43%
52-Week Range $3.70 - 9.22
Shares Outstanding (Mil)19.35

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 60 50
EPS ($) -1.81 1.18 0.62
EPS without NRI ($) -1.81 1.18 0.62
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for GLYC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Will GlycoMimetics (GLYC) Continue to Surge Higher? May 26 2016
The 3 Best Developmental Stage Biotech Stocks Surging Now May 25 2016
GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational... May 25 2016
2:01 pm GlycoMimetics announces published study in Science Translational Medicine pointing to... May 25 2016
GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational... May 25 2016
Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to... May 19 2016
Initial Efficacy Data for GlycoMimetics’ GMI-1271 Combined with Chemotherapy in Patients with AML... May 19 2016
GLYCOMIMETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 18 2016
GLYCOMIMETICS INC Financials May 10 2016
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 04 2016
GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report May 04 2016
GlycoMimetics Reports First Quarter 2016 Results May 04 2016
GlycoMimetics reports 1Q loss May 04 2016
GlycoMimetics reports 1Q loss May 04 2016
GlycoMimetics Reports First Quarter 2016 Results May 04 2016
GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented... Apr 25 2016
GLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 29 2016
GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Mar 21 2016
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors Mar 21 2016
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors Mar 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)